 Connection
Mayumi Nakagawa to Treatment Outcome
This is a "connection" page, showing publications Mayumi Nakagawa has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.198 |
|
|
|
-
Shibata T, Shah S, Evans T, Coleman H, Lieblong BJ, Spencer HJ, Quick CM, Sasagawa T, Stephens OW, Peterson E, Johann D, Lu YC, Nakagawa M. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. Front Immunol. 2021; 12:645299.
Score: 0.094
-
Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol. 2015 Jul; 22(7):679-87.
Score: 0.060
-
Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec; 146(12):1431-3.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|